Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies. - Chen LY; Aleman A; Larrayoz M; Chiu H; Zhao J; Van Oekelen O; Kelly G; Kim-Schulze S; Lagana A; Jagannath S; Chow TT; Lozano T; et al. (Blood, 2026)